Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for Hearing Loss in Congenital CMV
NCT01655212Phase 3Terminated
- Start
- Jun 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in congenital cytomegalovirus infection (cCMV). Started Jun 2012; status: terminated.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT01655212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655212.